Arcturus Therapeutics (ARCT) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Company overview and technology

• Focuses on mRNA vaccines and therapeutics, leveraging next-generation self-amplifying mRNA and proprietary LUNAR delivery technology.

• Strategic partnerships include CSL, CF Foundation, BARDA, and Meiji for global reach and program support.

• Manufacturing expertise in large mRNA molecules and cell-type optimized delivery differentiates the platform.

• Board strengthened by the addition of Moncef Slaoui, former Operation Warp Speed leader.

Vaccine pipeline and commercialization

• Kostaive, a self-amplifying mRNA vaccine, approved in Japan and launching soon, with European approval expected later this year.

• Bivalent and XBB trials ongoing, with global data collection to support US applications.

• Pandemic flu program, supported by BARDA and CSL, to begin in Q4, with significant government funding and stockpiling potential.

• Up to $4.3 billion in milestone payments from partnerships, with $200 million already received and commercial milestones imminent.

• Joint venture manufacturing facility in Japan nearing GMP certification, enabling government dose orders.

Clinical data and product differentiation

• Kostaive phase III data show strong efficacy, especially against Delta, and superior durability at lower doses compared to competitors.

• Six-month data published; twelve-month durability data to be presented soon.

• Platform demonstrates higher antibody levels and extended protection with lower doses.